# Octagon Capital Advisors LP 13F Q2 2026: $1.1 billion

Octagon Capital Advisors LP reported $1.1 billion in 13F securities across 27 positions for the quarter ended June 30, 2026, in a holdings report filed August 14, 2026. Its largest holding was Dianthus Therapeutics Inc at $180 million, 16.1% of the reported value. Since Q1 2026 it opened 5 new positions and exited 7.

SpecStream is the live web data engine for teams and agents. It reads the SEC's Form 13F data sets each quarter, and this page is that reading, keyed on the manager's CIK and the security's CUSIP. Ask for the managers or the holdings you track, and each new 13F filing arrives in your sheet, CRM, Slack or agent as the SEC publishes it.

- Quarter: Q2 2026, the quarter ended June 30, 2026
- Reported value: $1,112,538,962
- Positions: 27
- Filed: August 14, 2026
- Report type: 13F holdings report
- CIK: 1839435
- Form 13F file number: 028-20958
- CRD number: 306424
- Business address: 654 Madison Avenue 21st Floor, New York, NY 10065
- SEC filing: [0001839435-26-000004](https://www.sec.gov/Archives/edgar/data/1839435/000183943526000004/0001839435-26-000004-index.htm)
- Investment adviser record: [Form ADV on SpecStream](https://specstream.ai/data/investment-advisers/firm/octagon-capital-advisors-lp-306424)

## Top 25 holdings by value

The largest of 27 positions by reported value at the end of the quarter ended June 30, 2026. Put and call options are marked in the class. Change is in shares or principal against the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value | Change since Q1 2026 |
| --- | --- | --- | --- | --- |
| [Dianthus Therapeutics Inc](https://specstream.ai/data/institutional-holders/dianthus-therapeutics-inc-252828108) | COM | 1,841,667 | $179.5 million | -105,000 |
| [Definium Therapeutics Inc](https://specstream.ai/data/institutional-holders/definium-therapeutics-inc-24477v105) | COM SHS | 2,950,000 | $138.8 million | +510,000 |
| [Abivax SA](https://specstream.ai/data/institutional-holders/abivax-sa-00370m103) | SPONSORED ADS | 993,000 | $132.3 million | +316,000 |
| [Cogent Biosciences Inc](https://specstream.ai/data/institutional-holders/cogent-biosciences-inc-19240q201) | COM | 2,350,000 | $90.9 million | No change |
| [Alumis Inc](https://specstream.ai/data/institutional-holders/alumis-inc-022307102) | COM | 2,830,700 | $79.7 million | No change |
| [Arrivent Biopharma Inc](https://specstream.ai/data/institutional-holders/arrivent-biopharma-inc-04272n102) | COM | 1,971,054 | $68.5 million | No change |
| [Taysha Gene Therapies Inc](https://specstream.ai/data/institutional-holders/taysha-gene-therapies-inc-877619106) | COM SHS | 9,693,244 | $66 million | +833,333 |
| [Bioage Labs Inc](https://specstream.ai/data/institutional-holders/bioage-labs-inc-09077v100) | COM | 1,748,000 | $42.8 million | No change |
| [Mirum Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/mirum-pharmaceuticals-inc-604749101) | COM | 338,900 | $39.7 million | No change |
| [Kymera Therapeutics Inc](https://specstream.ai/data/institutional-holders/kymera-therapeutics-inc-501575104) | COM | 310,000 | $35.5 million | -115,000 |
| [Aktis Oncology Inc](https://specstream.ai/data/institutional-holders/aktis-oncology-inc-01021m104) | COM | 960,847 | $31 million | No change |
| [Xenon Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/xenon-pharmaceuticals-inc-98420n105) | COM | 490,000 | $29.6 million | No change |
| Erasca Inc | CALL (call) | 1,255,000 | $23 million | New |
| [Palisade Bio Inc](https://specstream.ai/data/institutional-holders/palisade-bio-inc-696389402) | COM | 10,276,317 | $21.5 million | No change |
| [Ocular Therapeutix Inc](https://specstream.ai/data/institutional-holders/ocular-therapeutix-inc-67576a100) | COM | 2,075,000 | $20.4 million | -1,091,600 |
| [Disc Medicine Inc](https://specstream.ai/data/institutional-holders/disc-medicine-inc-254604101) | COM | 270,000 | $19.7 million | No change |
| [Summit Therapeutics Inc](https://specstream.ai/data/institutional-holders/summit-therapeutics-inc-86627t108) | COM | 1,250,000 | $18.2 million | New |
| [Pharvaris N V](https://specstream.ai/data/institutional-holders/pharvaris-n-v-n69605108) | COM | 456,721 | $15.8 million | +291,721 |
| [Adlai Nortye LTD](https://specstream.ai/data/institutional-holders/adlai-nortye-ltd-00704r109) | SPONSORED ADS | 934,716 | $10.7 million | New |
| [Precision Biosciences Inc](https://specstream.ai/data/institutional-holders/precision-biosciences-inc-74019p207) | COM NEW | 1,350,000 | $10.6 million | -886,732 |
| [DBV Technologies S a](https://specstream.ai/data/institutional-holders/dbv-technologies-s-a-23306j309) | SPONSORED ADS | 574,200 | $9.4 million | No change |
| [Faeth Therapeutics Inc](https://specstream.ai/data/institutional-holders/faeth-therapeutics-inc-81728a207) | COM NEW | 361,010 | $9 million | New |
| [Gyre Therapeutics Inc](https://specstream.ai/data/institutional-holders/gyre-therapeutics-inc-403783103) | COM | 954,416 | $6.3 million | New |
| [Trevi Therapeutics Inc](https://specstream.ai/data/institutional-holders/trevi-therapeutics-inc-89532m101) | COM | 315,000 | $5.9 million | -1,170,000 |
| [Unicycive Therapeutics Inc](https://specstream.ai/data/institutional-holders/unicycive-therapeutics-inc-90466y202) | COM NEW | 1,000,000 | $4.7 million | No change |

## New positions in Q2 2026

5 positions not in the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| Erasca Inc | CALL (call) | 1,255,000 | $23 million |
| [Summit Therapeutics Inc](https://specstream.ai/data/institutional-holders/summit-therapeutics-inc-86627t108) | COM | 1,250,000 | $18.2 million |
| [Adlai Nortye LTD](https://specstream.ai/data/institutional-holders/adlai-nortye-ltd-00704r109) | SPONSORED ADS | 934,716 | $10.7 million |
| [Faeth Therapeutics Inc](https://specstream.ai/data/institutional-holders/faeth-therapeutics-inc-81728a207) | COM NEW | 361,010 | $9 million |
| [Gyre Therapeutics Inc](https://specstream.ai/data/institutional-holders/gyre-therapeutics-inc-403783103) | COM | 954,416 | $6.3 million |

## Positions exited in Q2 2026

7 positions in the filing for the quarter ended March 31, 2026 and not in this one, with the shares and value reported then.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| Centessa Pharmaceuticals PLC | SPONSORED ADS | 750,000 | $29.8 million |
| Kalvista Pharmaceuticals Inc | COM | 1,450,000 | $29.2 million |
| Terns Pharmaceuticals Inc | COM | 530,000 | $27.9 million |
| [Bridgebio Oncology Therapeut](https://specstream.ai/data/institutional-holders/bridgebio-oncology-therapeut-107924102) | COM NEW | 719,000 | $6.4 million |
| [Lexeo Therapeutics Inc](https://specstream.ai/data/institutional-holders/lexeo-therapeutics-inc-52886x107) | COM | 1,100,000 | $6.3 million |
| [Perspective Therapeutics Inc](https://specstream.ai/data/institutional-holders/perspective-therapeutics-inc-46489v302) | COM NEW | 791,555 | $3.3 million |
| [Evommune Inc](https://specstream.ai/data/institutional-holders/evommune-inc-30054y107) | COM SHS | 143,472 | $3.3 million |

## Also on SpecStream

- [Octagon Capital Advisors LP Form 13F filing on EDGAR](https://www.sec.gov/Archives/edgar/data/1839435/000183943526000004/0001839435-26-000004-index.htm)
- [Octagon Capital Advisors LP investment adviser record (Form ADV)](https://specstream.ai/data/investment-advisers/firm/octagon-capital-advisors-lp-306424)
- [Largest 13F filers in New York](https://specstream.ai/data/institutional-holdings/state/new-york)
- [Largest institutional managers by 13F value](https://specstream.ai/data/institutional-holdings)
- [Most widely held securities in 13F filings](https://specstream.ai/data/institutional-holders)

Source: [the SEC's Form 13F data sets](https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets). Public data published by the US Securities and Exchange Commission (US government work). Managers report these holdings themselves in Form 13F, and the SEC does not check or guarantee them. Form 13F lists long positions in US listed equities, some options and convertible notes held at the end of the quarter, and leaves out short positions, cash, most bonds and holdings below the reporting threshold. Values are market values in US dollars as the manager filed them. A manager can ask the SEC to keep some positions confidential for a time. This page uses SEC data and is not endorsed or certified by the SEC.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in New York, New York

- [Courier and delivery companies in New York, New York](https://specstream.ai/data/businesses/courier-and-delivery-companies/new-york-new-york-united-states)
- [Occupational therapy clinics in New York, New York](https://specstream.ai/data/businesses/occupational-therapy-clinics/new-york-new-york-united-states)
- [Bankruptcy law firms in New York, New York](https://specstream.ai/data/businesses/bankruptcy-law-firms/new-york-new-york-united-states)
- [Insurance agencies in New York, New York](https://specstream.ai/data/businesses/insurance-agencies/new-york-new-york-united-states)
- [Taiwanese restaurants in New York, New York](https://specstream.ai/data/businesses/taiwanese-restaurants/new-york-new-york-united-states)
- [Educational research institutes in New York, New York](https://specstream.ai/data/businesses/educational-research-institutes/new-york-new-york-united-states)
